Compare Cardinal Health Inc (CAH) vs Freeport-McMoRan Inc (FCX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cardinal Health Inc vs Freeport-McMoRan Inc — how do they compare? Cardinal Health Inc trades at $231.36 (market cap $54.46B), while Freeport-McMoRan Inc trades at $66.88 (market cap $96.91B). The key difference: Freeport-McMoRan Inc is the larger of the two by market cap, and Cardinal Health Inc pays the higher dividend (0.88%). Which is the better fit depends on your goals.
| CAH | FCX | |
|---|---|---|
Market Cap | $54.46B | $96.91B |
Sector | Health | Basic Materials |
52-Week High | $240.26 | $71.73 |
52-Week Low | $146.04 | $35.34 |
Enterprise Value | $58.49B | $103.19B |
Dividend Yield | 0.88% | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cardinal Health (CAH) trades at $231.24, down 3.75% on the day, following a strong earnings beat in Q2 2026 with EPS of $2.91 versus $2.42 expected. The stock is in a bullish technical trend with moving averages supporting further upside, while fundamentals show robust revenue growth and improved profitability, with a net income margin of 0.67% for 2025. Recent news highlights record highs post-earnings and optimistic fiscal 2027 guidance.
The outlook for CAH is positive, driven by consistent earnings beats, strong analyst buy ratings (54.55%), and a consensus price target of $270.11 implying significant upside. Key risks include high leverage with a debt-to-asset ratio of 16.09 and reliance on pharmaceutical and specialty business segments for growth amidst competitive pressures.
FCX trades at $66.83, down 2.98% on the day, but maintains a bullish technical trend with strong analyst support. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 expected at $0.72 EPS. Revenue remains stable around $25.9B, while net income margin improved to 11.38% in 2026. Recent news highlights operational challenges like lower copper volumes but also growth initiatives at Grasberg and Bagdad.
The outlook is positive with a consensus price target of $73.85, implying ~10% upside. Key opportunities include exposure to high copper prices and expansion projects, while risks involve production volatility, cost pressures, and reliance on commodity cycles. The stock's valuation appears elevated with a P/E of 33.93, requiring sustained earnings growth to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →About Freeport-McMoRan Inc
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →
